Guangzhou LBP Medicine Science & Technology Co., Ltd.

Shanghai Stock Exchange 688393.SS

Guangzhou LBP Medicine Science & Technology Co., Ltd. EBIT Margin for the year ending December 31, 2023: 3.91%

Guangzhou LBP Medicine Science & Technology Co., Ltd. EBIT Margin is 3.91% for the year ending December 31, 2023, a -37.35% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Guangzhou LBP Medicine Science & Technology Co., Ltd. EBIT Margin for the year ending December 31, 2022 was 6.25%, a -69.29% change year over year.
  • Guangzhou LBP Medicine Science & Technology Co., Ltd. EBIT Margin for the year ending December 31, 2021 was 20.35%, a -23.54% change year over year.
  • Guangzhou LBP Medicine Science & Technology Co., Ltd. EBIT Margin for the year ending December 31, 2020 was 26.62%, a 8.95% change year over year.
  • Guangzhou LBP Medicine Science & Technology Co., Ltd. EBIT Margin for the year ending December 31, 2019 was 24.43%, a 0.36% change year over year.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
Loading...
Shanghai Stock Exchange: 688393.SS

Guangzhou LBP Medicine Science & Technology Co., Ltd.

CEO Mr. Xiangting Cai
IPO Date Aug. 20, 2020
Location China
Headquarters Building 7
Employees 907
Sector Health Care
Industries
Description

Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China. It offers pathological diagnostic reagents and ancillary equipment, including liquid-based cytology, such as gynecological series, non-gynecological series, and equipment; fluorescence in situ hybridization products for various applications in breast, bladder, lung, cervical, prostate, and thyroid cancer; and neuroblastoma, soft tissue sarcoma, other solid tumors, prenatal screening and abortion, oligodendrocytes tumor, lymphoma, multiple myeloma, chronic myelogenous and lymphocytic leukemia, myelodysplastic syndromes, acute myeloid leukemia, and acute lymphoblastic leukemia. The company also provides immunohistochemistry products, which comprise antibodies, detection systems, repair systems, complementary products, and immunohistochemistry kit, as well as molecular genetic diagnosis products. Guangzhou LBP Medicine Science & Technology Co., Ltd. was founded in 2005 and is based in Guangzhou, China.

Similar companies

688338.SS

Beijing Succeeder Technology Inc.

USD 3.27

2.18%

688580.SS

Nanjing Vishee Medical Technology Co., Ltd

USD 3.72

5.33%

688108.SS

Sino Medical Sciences Technology Inc.

USD 1.31

3.77%

688026.SS

Guangzhou Jet Bio-Filtration Co., Ltd.

USD 1.70

4.79%

688085.SS

Shanghai Sanyou Medical Co., Ltd.

USD 2.79

4.08%

StockViz Staff

January 16, 2025

Any question? Send us an email